首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   2613896篇
  免费   186611篇
  国内免费   7631篇
耳鼻咽喉   34480篇
儿科学   86062篇
妇产科学   72348篇
基础医学   367148篇
口腔科学   70169篇
临床医学   239135篇
内科学   520081篇
皮肤病学   62874篇
神经病学   216060篇
特种医学   100308篇
外国民族医学   736篇
外科学   388669篇
综合类   50688篇
现状与发展   5篇
一般理论   1014篇
预防医学   199528篇
眼科学   56985篇
药学   189518篇
  8篇
中国医学   5385篇
肿瘤学   146937篇
  2021年   20539篇
  2019年   21186篇
  2018年   29927篇
  2017年   23040篇
  2016年   26673篇
  2015年   30075篇
  2014年   41271篇
  2013年   61708篇
  2012年   82083篇
  2011年   86487篇
  2010年   52140篇
  2009年   50081篇
  2008年   80884篇
  2007年   85734篇
  2006年   87439篇
  2005年   83518篇
  2004年   80453篇
  2003年   77672篇
  2002年   74903篇
  2001年   128573篇
  2000年   131442篇
  1999年   110725篇
  1998年   31558篇
  1997年   28186篇
  1996年   28452篇
  1995年   27583篇
  1994年   25262篇
  1993年   23607篇
  1992年   85280篇
  1991年   81656篇
  1990年   78876篇
  1989年   76142篇
  1988年   69552篇
  1987年   68076篇
  1986年   63601篇
  1985年   60579篇
  1984年   45059篇
  1983年   38060篇
  1982年   22599篇
  1981年   20126篇
  1979年   39038篇
  1978年   27496篇
  1977年   23307篇
  1976年   21540篇
  1975年   22857篇
  1974年   26841篇
  1973年   25407篇
  1972年   23775篇
  1971年   21972篇
  1970年   20201篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Introduction: The landscape of poly (ADP-ribose) polymerase (PARP) inhibition in ovarian cancer is rapidly evolving and becoming increasingly complex. Ovarian cancer is leading therapeutic innovation by providing the proof of concept for DNA repair as a target. Three different PARP inhibitors have now received approvals in the US and Europe in different indications. Subtle but crucial differences can be found among the licensed indications for each PARP inhibitor in terms of histology, type of BRCA mutation (germline and/or somatic), number of prior lines of chemotherapy and whether the indication is in the treatment or maintenance settings.

Areas covered: We review the latest clinical data regarding the PARP inhibitor rucaparib in ovarian cancer, provide an update on the evolving landscape of PARP inhibition in ovarian cancer, and summarize avenues of ongoing and future research.

Expert opinion: All eligible patients should be offered a PARP inhibitor. SOLO1 trial results demonstrated an unprecedented benefit maintenance with PARP inhibitors in first line. Results from trials evaluating PARP inhibitors as maintenance in first line regardless of BRCA status and from trials evaluating combinatorial strategies are eagerly awaited.  相似文献   

2.
3.
4.
Individuals with sudden unilateral deafness offer a unique opportunity to study plasticity of the binaural auditory system in adult humans. Stimulation of the intact ear results in increased activity in the auditory cortex. However, there are no reports of changes at sub-cortical levels in humans. Therefore, the aim of the present study was to investigate changes in sub-cortical activity immediately before and after the onset of surgically induced unilateral deafness in adult humans. Click-evoked auditory brainstem responses (ABRs) to stimulation of the healthy ear were recorded from ten adults during the course of translabyrinthine surgery for the removal of a unilateral acoustic neuroma. This surgical technique always results in abrupt deafferentation of the affected ear. The results revealed a rapid (within minutes) reduction in latency of wave V (mean pre = 6.55 ms; mean post = 6.15 ms; p < 0.001). A latency reduction was also observed for wave III (mean pre = 4.40 ms; mean post = 4.13 ms; p < 0.001). These reductions in response latency are consistent with functional changes including disinhibition or/and more rapid intra-cellular signalling affecting binaurally sensitive neurons in the central auditory system. The results are highly relevant for improved understanding of putative physiological mechanisms underlying perceptual disorders such as tinnitus and hyperacusis.  相似文献   
5.
6.
Abstract

Objective: To understand the origin of extremely high gonadotropin levels in a perimenopausal woman.

Methods: A 52-year-old woman with a 2?months of amenorrhea followed spontaneous menstrual cycles recovery was referred to our outpatient clinic with elevated follicle-stimulating hormone (FSH, 483 mUI/ml), luteinizing hormone (LH, 475 mUI/ml) and prolactin (PRL, 173?ng/ml). She was known to take levosulpiride. The gonadotropin levels did not fit with the clinical features.

Results: A gonadotroph tumor was ruled out. Further analysis confirmed constantly high FSH, LH and PRL levels. The measurements were repeated using different analytical platforms with different results. After serial dilutions, nonlinearity was present suggesting an immunoassay interference. After post-polyethylene glycol recovery, hormone levels appeared in the normal range. Anti-goat antibodies were recognized in the serum of the patient.

Conclusions: This case report shows a case of falsely abnormal high gonadotropin and PRL levels in a woman during menopause transition. In the clinical practice the evaluation of gonadotropin profile is not recommended at this age, but the abnormal levels stimulated further evaluation. An interference in the assay due to anti-goat antibodies resulted in abnormally high level of FSH and LH. A strict collaboration between clinicians and the laboratory is needed, when laboratory findings do not correspond to clinical findings.  相似文献   
7.
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号